Périatérite noueuse et infection par le parvovirus B19

Gaches, F.; Loustaud, V.; Vidal, É.; Delaire, L; Guiard–Schmid, Jean–Baptiste; Lavoine, É.; Negrier, Ph.; Liozon, F

doi:10.1016/s0248-8663(05)81309-8

Cited by 23 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 A positive serological test for B19 has been reported in a few patients with polyarteritis nodosa (PAN). [2][3][4] As far as we know no studies of B19 DNA in tissue samples of patients with PAN have been published, so we used a nested polymerase chain reaction (PCR) approach to screen for B19 DNA in fixed paraffin embedded tissue samples from patients with PAN and microscopic polyangiitis (MPA). The diagnosis was based on the Chapell-Hill Consensus Conference guidelines.…”

mentioning

confidence: 99%

No evidence of parvovirus B19 in tissue samples from patients with polyarteritis nodosa and microscopic polyangiitis as assessed by the polymerase chain reaction

Sachetto

2006

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

in 6/7 patients. Steroid dosages were reduced in 9/12 (75%) patients, with a significant reduction from a mean (SD) of 20.2 (9.4) mg/day to 11.6 (5.5) mg/day (p = 0.03).The obvious weakness in this study includes the relatively small numbers of patients who completed the trial, and the follow up was too short to examine the efficacy of leflunomide for long term renal preservation. In addition, our patients were a heterogeneous group with different renal histological classes who had been treated previously with multiple immunosuppressive agents for variable lengths of time. For these reasons, the possibility that the observed improvement, was due in part to corticosteroid or other immunosuppressant drugs given previously cannot be excluded in the absence of a control group. Another limitation includes the correlation of the clinical response with renal histological features that were obtained at a mean of 16 months before leflunomide treatment. Furthermore, repeat renal histology was not available after treatment. In conclusion, leflunomide is a safe and probably efficacious treatment in patients with lupus nephritis who do not respond or cannot tolerate conventional treatments.We thank Aventis for providing the leflunomide that was used in this study.

show abstract

mentioning

confidence: 99%